|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saini S, Yamamura S, Majid S, Shahryari V,
Hirata H, Tanaka Y and Dahiya R: MicroRNA-708 induces apoptosis and
suppresses tumorigenicity in renal cancer cells. Cancer Res.
71:6208–6219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu ZH, Zhang Q, Wang YD, Chen J, Jiang ZM,
Shi M, Guo X, Qin J, Cui GH, Cai ZM, et al: Overexpression of
cyclooxygenase-1 correlates with poor prognosis in renal cell
carcinoma. Asian Pac J Cancer Prev. 14:3729–3734. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bertone P, Stolc V, Royce TE, Rozowsky JS,
Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, et
al: Global identification of human transcribed sequences with
genome tiling arrays. Science. 306:2242–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song SJ and Pandolfi PP: miR-22 in
tumorigenesis. Cell cycle. 13:11–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen B, Tang H, Liu X, Liu P, Yang L, Xie
X, Ye F, Song C, Xie X and Wei W: miR-22 as a prognostic factor
targets glucose transporter protein type 1 in breast cancer. Cancer
Lett. 356:410–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jafarzadeh-Samani Z, Sohrabi S,
Shirmohammadi K, Effatpanah H, Yadegarazari R and Saidijam M:
Evaluation of miR-22 and miR-20a as diagnostic biomarkers for
gastric cancer. Chin Clin Oncol. 6:162017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Tang J, Li C, Kong J, Wang J, Wu
Y, Xu E and Lai M: MiR-22 regulates 5-FU sensitivity by inhibiting
autophagy and promoting apoptosis in colorectal cancer cells.
Cancer Lett. 356:781–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang C, Ning S, Li Z, Qin X and Xu W:
miR-22 is down-regulated in esophageal squamous cell carcinoma and
inhibits cell migration and invasion. Cancer Cell Int. 14:1382014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zuo QF, Cao LY, Yu T, Gong L, Wang LN,
Zhao YL, Xiao B and Zou QM: MicroRNA-22 inhibits tumor growth and
metastasis in gastric cancer by directly targeting MMP14 and Snail.
Cell Death Dis. 6:e20002015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan W, Huang J, Xiao H and Liang Z:
MicroRNA-22 is downregulated in clear cell renal cell carcinoma,
and inhibits cell growth, migration and invasion by targeting PTEN.
Mol Med Rep. 13:4800–4806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Orom UA, Derrien T, Beringer M, Gumireddy
K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q,
et al: Long noncoding RNAs with enhancer-like function in human
cells. Cell. 143:46–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Szymanski M, Barciszewska MZ, Erdmann VA
and Barciszewski J: A new frontier for molecular medicine:
noncoding RNAs. Biochim Biophys Acta. 1756:65–75. 2005.PubMed/NCBI
|
|
16
|
Han Y, Liu Y, Gui Y and Cai Z: Long
intergenic non-coding RNA TUG1 is overexpressed in urothelial
carcinoma of the bladder. J Surg Oncol. 107:555–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li
SQ, Wang CM, Tong YS, Tuo L, Wu M, et al: Long noncoding RNA
SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and
associated with poor prognosis. Tumour Biol. 35:7743–7754. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long Noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
Interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian X and Xu G: Clinical value of lncRNA
MALAT1 as a prognostic marker in human cancer: Systematic review
and meta-analysis. BMJ Open. 5:e0086532015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luan W, Li L, Shi Y, Bu X, Xia Y, Wang J,
Djangmah HS, Liu X, You Y and Xu B: Long non-coding RNA MALAT1 acts
as a competing endogenous RNA to promote malignant melanoma growth
and metastasis by sponging miR-22. Oncotarget. 7:63901–63912. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Chen Z, Wang X, Huang Z, He Z and
Chen Y: Long non-coding RNA: A new player in cancer. J Hematol
Oncol. 6:372013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu MH, Tang B, Zeng S, Hu CJ, Xie R, Wu
YY, Wang SM, He FT and Yang SM: Long noncoding RNA BC032469, a
novel competing endogenous RNA, upregulates hTERT expression by
sponging miR-1207-5p and promotes proliferation in gastric cancer.
Oncogene. 35:3524–3534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ,
Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA
activated by TGF-β promotes the invasion-metastasis cascade in
hepatocellular carcinoma. Cancer Cell. 25:666–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei Y and Niu B: Role of MALAT1 as a
prognostic factor for survival in various cancers: A systematic
review of the literature with meta-analysis. Dis Markers.
2015:1646352015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gutschner T, Hammerle M and Diederichs S:
MALAT1 - a paradigm for long noncoding RNA function in
cancer. J Mol Med. 91:791–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu F, Lu Z, Cai J, Huang K, Chen B, Li G,
Dong P and Zheng J: MALAT1 functions as a competing endogenous RNA
to mediate Rac1 expression by sequestering miR-101b in liver
fibrosis. Cell Cycle. 14:3885–3896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu H, He Y, Lin L, Qi Z, Ma L, Li L and Su
Y: Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+
cervical cancer via sponging miR-145. Tumour Biol. 37:1683–1691.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng
J, Xiao W, Yu G, Yao W, Zhou H, et al: LncRNA MALAT1 functions as a
competing endogenous RNA to regulate ZEB2 expression by sponging
miR-200s in clear cell kidney carcinoma. Oncotarget. 6:38005–38015.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiong J: Emerging roles of microRNA-22 in
human disease and normal physiology. Curr Mol Med. 12:247–258.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Budd WT, Seashols-Williams SJ, Clark GC,
Weaver D, Calvert V, Petricoin E, Dragoescu EA, O'Hanlon K and
Zehner ZE: Dual action of miR-125b as a tumor suppressor and
OncomiR-22 promotes prostate cancer tumorigenesis. PLoS One.
10:e01423732015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Palacios F, Abreu C, Prieto D, Morande P,
Ruiz S, Fernández-Calero T, Naya H, Libisch G, Robello C, Landoni
AI, et al: Activation of the PI3K/AKT pathway by microRNA-22
results in CLL B-cell proliferation. Leukemia. 29:115–125. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Zhang D, Yi C, Wang Y, Wang H and
Wang J: MicroRNA-22 functions as a tumor suppressor by targeting
SIRT1 in renal cell carcinoma. Oncol Rep. 35:559–567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang Y, Jin X, Xiang Y, Chen Y, Shen CX,
Zhang YC and Li YG: The lncRNA MALAT1 protects the endothelium
against ox-LDL-induced dysfunction via upregulating the expression
of the miR-22-3p target genes CXCR2 and AKT. FEBS Lett.
589:3189–3196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei
M, Wang L and Zhong M: Leptin regulates proliferation and apoptosis
of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J
Biosci. 37:91–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang C, Mao ZP, Wang L, Wu GH, Zhang FH,
Wang DY and Shi JL: Long non-coding RNA MALAT1 promotes
cholangiocarcinoma cell proliferation and invasion by activating
PI3K/Akt pathway. Neoplasma. 64:725–731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren
Y, Wu Y, Mei M, Zhang L and Wang X: Long non coding RNA MALAT1
promotes tumor growth and metastasis by inducing
epithelial-mesenchymal transition in oral squamous cell carcinoma.
Sci Rep. 5:159722015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han
Z, Sui H, Tang Y, Wang Y, Liu N, et al: Long non-coding RNA MALAT1
promotes tumour growth and metastasis in colorectal cancer through
binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2
complex. Br J Cancer. 111:736–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
